---
Commercialization
Commercialization:
Revenue generation: near-term through a limited number of wholly owned clinics in Europe and also through out-licencing partnerships into the US addiction treatment clinic industry; medium-term revenue generation through therapeutics commercialization.
Clinics
Build the platform to deploy the therapeutics developed in our R&D business while generating clinical data and revenue and treating clients.
Commercialization: Therapeutics Commercialization
Enable third party addiction treatment centres deploy more effective treatments to patients.
Purpose:
To commercialize our proprietary Ketamine-assisted therapy package for the treatment of AUD beyond our physical footprint. Disrupting the North American addiction treatment market through licensing our ground breaking therapeutics package
Licensing partnerships outside UK and Europe for the Awakn KARE methodology
Proposition:
• Access to KARE proprietary IP
• Training
• Systems
• Clinic design and new-site activation support
Target Audience:
Existing addiction treatment clinic’s throughout the US and Canada
Sign Up for Newsletter
MAIN OFFICE
18 Dukes Road,
London WC1H 9PY, United Kingdom
UK OFFICE
1 Regent Street, Bristol, BS8 4HW, United Kingdom
© 2021 Awakn Life Sciences Corp | Privacy Policy | Appropriate Use Policy